期刊文献+

糖皮质激素及嘌呤类似物在炎症性肠病治疗中的应用与评价 被引量:8

Treatment of Inflammatory Bowel Diseases with Glucocorticoid Purine Analogue
暂未订购
导出
摘要 目的:合理应用糖皮质激素及嘌呤类似物治疗炎症性肠病。方法:复习文献,总结糖皮质激素及嘌呤类似物治疗炎症性肠病的适应证、用药时机、疗程、疗效及不良反应。结果及结论:糖皮质激素适用于氨基水杨酸制剂疗效不佳的轻、中型患者,尤其适用于重型活动期及暴发型患者;应根据患者炎症性肠病病变的程度和范围选择合适的剂量、给药方式,注意药品不良反应。嘌呤类似物主要适用于对糖皮质激素依赖的UC病例及维持缓解用药以及激素疗效不佳的轻、中度炎症、瘘管性病变以及激素依赖的CD病例。起效慢,不单独用于急性期的治疗;不良反应存在个体差异,用于维持缓解,宜长期用药。 OBJECTIVE: To use glucocorticoid and purine analogue rationally for the treatment of inflammatory bowel diseases. METHODS: The pertinent literature was reviewed, and the indications, medication time, course of treatment, curative effect and adverse drug reations of the glucocorticoid and purine analogue in the treatment of inflammatory bowel diseases were summarized. RESULTS & CONCLUSION: Glucocorticoid is indicated for patients with mild or mediuim types of inflammatory bowel diseases who had a poor response to aminosalicylic acid, especially to severe type on active phase and fulminating type. The choice of dosage and route of administration should be based on the degree and extent of inflammatory bowel diseases, meanwhile, the adverse drugs reactions should be monitored. Purine analogue is indicated for glucocorticoid - dependent ulcerative colitis (UC) cases, maintainable remission, mild or mediuim types of inflammatory bowel diseases, fistula diseases, and hormone dependent Crohn's disease (CD) cases. Because of the slow onset of drug effect of purine analogue, which shouldn't be used alone for acute stage treatment; there was individual variation for its adverse drug reactions, and long - term medication is advisable for remission maintenance.
作者 杨雪松
出处 《中国医院用药评价与分析》 2008年第8期569-571,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 炎症性肠病 溃疡性结肠炎 克罗恩病 糖皮质激素 嘌呤类似物 治疗学 Inflammatory bowel disease Ulcerative colitis Crohn ' s disease, Glucocorticoid Purine analogue Therapeutics
  • 相关文献

参考文献6

二级参考文献48

  • 1韩英.溃疡性结肠炎的临床维持缓解治疗评价[J].中国医院用药评价与分析,2004,4(6):338-341. 被引量:13
  • 2Weinshilboum RM,Sladek SL.Mercaptopurine pharmacogenetics:monogenic inheritance of erythrocyte thiopurine methyltransferase activity.Am J Hum Genet,1980,32:651-666.
  • 3Gisbert JP,Gomollon F,Cara C,et al.Thiopurine methyltransferase activity in the inflammatory bowel disease:a study on 7046 Spanish patients.Med Clin (Barc),2005,125:281-285.
  • 4Colombel JF,Ferrari N,Debuysere H,et al.Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.Gastroenterology,2000,118:1025-1030.
  • 5Dervieux T,Meyer G,Barham R,et al.Liquid chromatographytandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy.Clin Chem,2005,51:2074-2084.
  • 6Gearry RB,Barclay ML,Roberts RL,et al.Thiopurine methyltransferase and 6-thioguanine nucleotide measurement:early experience of use in clinical practice.Intern Med J,2005,35:580-585.
  • 7Rebecca L,Robertsa,Murray L,et al.A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations.Clin Chim Acta,2004,341:49-53.
  • 8Winter J,Walker A,Shapiro D,et al.Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.Aliment Pharmacol Ther,2004,20:593-599.
  • 9Gearry RB,Barclay ML.Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.J Gastroenterol Hepatol,2005,20:1149-1157.
  • 10Goldenberg BA,Rawsthorne P,Bernstein CN.The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.Am J Gastroenterol,2004,99:1744-1748.

共引文献27

同被引文献75

引证文献8

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部